Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740172 | 1.00 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14739740 | 1.00 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14739557 | 1.00 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14740431 | 1.00 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14739559 | 1.00 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14739741 | 1.00 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14740175 | 1.00 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14740429 | 1.00 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14739528 | 1.00 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14739844 | 0.92 | CNR1 (0.70) | CNR1ALDH1A1FAAHCNR2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | claimed |
| EP-3210972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Catabasis Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170073305-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073305-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073305-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| EP-2751071-A2 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | Milne, Jill C. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2013033602-A2 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | MILNE JILL C (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033602-A2 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | MILNE JILL C (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | FASN, FADS1, ELOVL5 | CNR1 1072/4885ALDH1A1 810/4885FAAH 29/4885 |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | CNR1 2881/4885ALDH1A1 3440/4885FAAH 282/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | CNR1 2881/4885ALDH1A1 3440/4885FAAH 282/4885 |
| US-20170073305-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | FASN, FADS1, ELOVL5 | CNR1 1072/4885ALDH1A1 810/4885FAAH 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.